ALK and metastatic neoplasm: Although the incidence of ALK-positive NCSLC only accounts for 5% of all NCSLC cases, the efficacy of tyrosine kinase inhibitors with ALK activity ensures that these agents will have a place in the treatment of advanced and metastatic disease.